1. Preventive portfolio scale-up - Swasthfit contributed 26% of revenue in Q3 FY26 and grew \~20% in Q1 FY27, with management expecting to sustain that rate on traction in Tier 2/3 towns. At roughly a quarter of revenue, sustaining \~20% growth adds about 5 percentage points to company growth without diluting margins.
2. Tier 3+ expansion - Tier 3+ geographies grew at a 16.7% CAGR from FY23 to FY26, reaching ₹1,090 crore or 39% of revenue, with cluster-based pricing keeping realisations intact. Management plans 12-15 new labs and 600-800 collection centers in FY27, weighted to these high-growth markets.
3. Network compounding - FY26 added 14 labs and over 1,100 collection centers, taking the network to 312 labs and 7,727 patient service centers. Each new center extends the hub-and-spoke model's reach, and patients serviced rose 1.5 million in FY26 to 30.3 million.
4. CGHS/ECHS price increase - New CGHS/ECHS rates effective late September 2025 are flowing through at an estimated 2-3% company-level benefit, expected to continue for at least 2-3 more quarters. Revenue per patient rose 10% YoY to ₹968 in Q1 FY27, partly on this increase.
5. Sovaaka premium launch - The AI-powered precision health brand opened its first fully company-owned center in Gurugram in January 2026, offering genetic testing, low-dose CT, and 1.5T MRI. Management is stabilising this center before scaling, with no additional centers planned in FY27.
6. Rural GraminFit program - The rural preventive healthcare program tested over 1,10,000 patients across 7 states in Q1 FY27, using a more affordable package than Swasthfit. This opens an underserved market where organized diagnostics penetration is low.
7. Advanced diagnostics depth - Launched 116 new tests in Q1 FY27 including 4 first-in-India tests, and 136 in FY26 with 13 first-in-India. Genomics remains under 5% of revenue, leaving headroom as high-complexity testing carries similar EBITDA margins to routine work.
8. Dubai subsidiary for M&A - DR LAL PATHLABS FZCO was incorporated in Dubai in June 2026 as a wholly owned subsidiary, with a mandate to invest in diagnostics including acquisitions, tie-ups, or joint ventures. This gives a regional vehicle for the 3-5 year Middle East and Africa expansion plan.
9. Shahbazkers Mumbai acquisition - Acquired 100% of Shahbazkers Diagnostic Centre in Mumbai for \~₹20 crore (3.3x FY26 revenue of ₹6.11 crore), filling a micro-market gap where Dr Lal PathLabs had no significant presence. The 45-year-old lab is expected to grow with the company's products and marketing deployed.